Triangle Securities Wealth Management Has $1.05 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Triangle Securities Wealth Management raised its stake in Bristol-Myers Squibb (NYSE:BMY) by 2.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 17,180 shares of the biopharmaceutical company’s stock after buying an additional 413 shares during the quarter. Triangle Securities Wealth Management’s holdings in Bristol-Myers Squibb were worth $1,048,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Pinney & Scofield Inc. bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $25,000. Park Square Financial Group LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $26,000. Fairway Wealth LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $28,000. Transce3nd LLC bought a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $28,000. Finally, Global Wealth Strategies & Associates raised its holdings in shares of Bristol-Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 275 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Samit Hirawat purchased 4,250 shares of the business’s stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares of the company’s stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.09% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BMY. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a report on Friday, April 25th. UBS Group lowered their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research note on Friday, April 11th. Jefferies Financial Group lowered their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research note on Wednesday, April 23rd. The Goldman Sachs Group reiterated a “neutral” rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Finally, Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $48.10 on Wednesday. The company has a 50-day moving average of $50.06 and a 200-day moving average of $55.24. The company has a market capitalization of $97.88 billion, a price-to-earnings ratio of -10.88, a PEG ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm’s revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period last year, the firm earned ($4.40) EPS. As a group, equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.